Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

New clinical insights support U.S. doctors in using transoral robotic surgery (TORS) to personalize treatment plans for ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

A South Carolina native and two-time Super Bowl champion celebrated a life win recently. Jim Stuckey is cancer-free after an extensive battle with head and neck ...